Want to see HK:0401 full AI Analyst Report?
Top Page
Wanjia Group Holdings Ltd.
(0401)
Select Model
Select Model
Rating:45Neutral
Price Target:
HK$0.09
▲(3.33% Upside)
Action:Reiterated
Date:08/05/26
The score is held down primarily by weak and inconsistent profitability and the latest-year cash flow reversal into negative territory, despite a comparatively manageable leverage profile. Technicals also lean negative with price below key moving averages and a negative MACD. Valuation does not provide support because the negative P/E is driven by losses and there is no dividend yield data.
Positive Factors
Manageable Leverage
Low and stable leverage gives Wanjia greater financial flexibility than a heavily indebted business. Limited debt expansion reduces refinancing pressure and preserves capacity to support operations, invest in its medical-distribution activities, or withstand periods of weaker profitability.
Negative Factors
Persistent Losses
Repeated net losses indicate that revenue has not translated into dependable earnings, weakening internal funding capacity and returns on equity. The history also makes any recovery less established, leaving profitability improvement as a central requirement for durable financial progress.
Read all positive and negative factors
Positive Factors
Negative Factors
Manageable Leverage
Low and stable leverage gives Wanjia greater financial flexibility than a heavily indebted business. Limited debt expansion reduces refinancing pressure and preserves capacity to support operations, invest in its medical-distribution activities, or withstand periods of weaker profitability.
Read all positive factors
Wanjia Group Holdings Ltd. (0401) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$107.22M
Dividend YieldN/A
Average Volume (3M)676.86K
Price to Earnings (P/E)―
Beta (1Y)0.75
Revenue Growth2.28%
EPS Growth-83.16%
CountryHK
Employees183
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)-0.02
Shares Outstanding1,128,615,700
10 Day Avg. Volume12,000
30 Day Avg. Volume676,859
Financial Highlights & Ratios
PEG Ratio-0.54
Price to Book (P/B)1.08
Price to Sales (P/S)0.55
P/FCF Ratio-10.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Wanjia Group Holdings Ltd. Business Overview & Revenue Model
Company Description
Wanjia Group Holdings Limited operates as an investment holding company, primarily engaged in the wholesale and distribution of pharmaceutical products across mainland China and Hong Kong. The firm also offers hemodialysis treatment and associated...
Wanjia Group Holdings Ltd. Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
62
Positive
Cash Flow
38
Negative
| Breakdown | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 165.38M | 161.69M | 181.09M | 173.70M | 154.82M |
| Gross Profit | 44.42M | 50.35M | 54.74M | 56.94M | 54.23M |
| EBITDA | -711.00K | 4.13M | -29.02M | 16.40M | -34.64M |
| Net Income | -9.86M | -6.62M | -39.98M | 1.82M | -51.00M |
Balance Sheet | |||||
| Total Assets | 132.58M | 106.82M | 117.10M | 173.45M | 191.82M |
| Cash, Cash Equivalents and Short-Term Investments | 33.03M | 24.08M | 18.23M | 9.88M | 5.77M |
| Total Debt | 12.21M | 11.72M | 15.60M | 25.17M | 24.49M |
| Total Liabilities | 47.31M | 38.19M | 41.91M | 53.22M | 63.72M |
| Stockholders Equity | 83.65M | 66.88M | 73.49M | 118.20M | 126.18M |
Cash Flow | |||||
| Free Cash Flow | -9.02M | 9.92M | 5.89M | 5.47M | -4.86M |
| Operating Cash Flow | -7.52M | 10.65M | 9.30M | 9.38M | 2.12M |
| Investing Cash Flow | -1.50M | -697.00K | 674.00K | -3.84M | -6.93M |
| Financing Cash Flow | 17.54M | -3.71M | -1.04M | -802.00K | -14.97M |
Wanjia Group Holdings Ltd. Technical Analysis
Negative
0.09
Price Trends
0.11
Negative
0.13
Negative
0.12
Negative
Market Momentum
>-0.01
Negative
32.03
Neutral
54.29
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0401, the sentiment is Negative. The current price of 0.09 is below the 20-day moving average (MA) of 0.10, below the 50-day MA of 0.11, and below the 200-day MA of 0.12, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 32.03 is Neutral, neither overbought nor oversold. The STOCH value of 54.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0401.
Wanjia Group Holdings Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$4.69B | 12.19 | 7.05% | 4.79% | 6.47% | 8.10% | |
65 Neutral | HK$45.90B | 5.66 | 8.33% | 5.29% | 2.78% | 7.71% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | HK$593.46M | 10.91 | 7.70% | 6.25% | 14.25% | 0.83% | |
45 Neutral | HK$107.22M | -5.00 | -19.15% | ― | 2.28% | -83.16% | |
42 Neutral | HK$648.60M | -7.24 | -2.60% | 17.10% | -2.55% | -145.60% | |
41 Neutral | HK$416.14M | -6.11 | -273.18% | ― | 5.52% | 56.54% |
* Healthcare Sector Average
HK:0401
Wanjia Group Holdings Ltd.
0.10
0.01
14.46%
HK:0673
China Health Group
0.30
-0.20
-40.00%
HK:1099
Sinopharm Group Co
14.92
-2.68
-15.24%
HK:1931
IVD Medical Holding Limited
0.40
-9.05
-95.82%
HK:2192
Medlive Technology Co., Ltd.
6.57
-5.66
-46.29%
HK:2289
Charmacy Pharmaceutical Co., Ltd. Class H
5.50
<0.01
0.18%
Wanjia Group Holdings Ltd. Corporate Events
Wanjia Group Wins Unanimous Shareholder Backing at AGM
Sep 11, 2026
Wanjia Group Holdings Ltd. reported that all resolutions proposed at its annual general meeting on 11 September 2026 were approved by shareholders voting by poll, with Tricor Investor Services Limited acting as scrutineer. The meeting covered adop...
Wanjia Group Details Auditor Re-Appointment and Fee Under New HKEX Guidelines
Aug 4, 2026
Wanjia Group Holdings Limited has issued a supplemental announcement to its AGM circular detailing the proposed re-appointment of HLB Hodgson Impey Cheng Limited as its auditor in line with updated Hong Kong Stock Exchange disclosure guidelines. T...
Wanjia Group Calls 2026 AGM to Approve Accounts, Board Changes and Share Mandate
Jul 30, 2026
Wanjia Group Holdings Ltd., incorporated in the Cayman Islands and listed on the Hong Kong Stock Exchange, operates under a conventional listed-company governance structure with a board made up of executive, non-executive and independent non-execu...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.